Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ConM SOSIP.v7 gp140 HIV vaccine phase 1 study
NL-OMON48531Phase 1Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of ConM SOSIP and MPLA liposomes in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Grade 3 adverse events within 7 days after each vaccination, Grade 3 and/or vaccine-related adverse events within 28 days after each vaccination and 1 more. Started Nov 2019; status: completed.
02
Drugs
ConM SOSIPMPLA liposomes
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON48531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48531.